The FDA has approved Gazyva (obinutuzumab) for the treatment of adult patients with active lupus nephritis who are receiving standard therapy.

Roche has received FDA approval for its antibody treatment Gazyva to be used in combination with standard therapy for adults with active lupus ...

Obinutuzumab (Gazyva) is the first drug to be approved for lupus nephritis since the approvals of belimumab (Benlysta) in 2020 and voclosporin (Lupkynis) in 2021.

The FDA has approved Genentech’s Gazyva (obinutuzumab) for the treatment of lupus nephritis in adults, according to a news release published today. Gazyva is the first and only anti-CD20 monoclonal ...

Simultaneous PD-1/VEGF/CTLA-4 blockade aims to compress multi-drug regimens into a single infusion, raising questions about ...

aThe Cardiac Exercise Research Group at the Faculty of Medicine and Health Sciences, Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway ...

Abbvie (($ABBV)) announced an update on their ongoing clinical study. AbbVie recently completed a Phase 2 clinical study ...